The economics of selective serotonin reuptake inhibitors in depression: A critical review

CNS Drugs

Volumn 15, Issue 1, 2001, Pages 59-83

  Frank, Lori ^a   Revicki, Dennis A ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEPRESSION; DRUG COST; DRUG RESEARCH; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

EID: 0035146873     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115010-00005     Document Type: Review

References (5)

1. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services, 1999
2. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the United States: based on five epidemiologic catchment area sites. Arch Gen Psychiatry 1988; 45 (11): 977-86
3. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151 (7): 979-86
4. Weissman MM, Bruce ML, Lef PJ, et al. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, 1991; 53-80
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study. Arch Gen Psychiatry 1994; 51: 8-19